Schizophrenia News and Research

Latest Schizophrenia News and Research

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Researchers find the genetic mutation that is linked with changes in brain development

For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.

19 Oct 2009

New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses

An innovative diagnostic technique invented by a Monash University researcher could dramatically fast-track the detection of mental and neurological illnesses.

19 Oct 2009

SAMHSA honors contributors to mental health recovery at the 2009 Voice Awards

Writers and producers from The Soloist, "Grey's Anatomy," "United States of Tara," "90210," and others were honored by the Substance Abuse and Mental Health Services Administration (SAMHSA) for increasing awareness of mental health issues and the power of recovery at the 2009 Voice Awards last night. The event was hosted by Academy Award-winning actor and mental health consumer Richard Dreyfuss at Paramount Studios in Los Angeles.

15 Oct 2009

Negative symptoms represent an attractive target for drug development

A half-day workshop on issues in the design of clinical trials to evaluate treatments for negative symptoms of schizophrenia, chaired by Stephen Marder, MD, UCLA Department of Psychiatry and David Daniel, M.D., United BioSource Corporation was held 5 October 2009, as part of the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in San Diego, CA.

15 Oct 2009

Medicure announces results of operations for the three months ended August 31, 2009

Medicure Inc., today reported the results of operations for the three months ended August 31, 2009 (Q1 2009/10). All amounts cited below are in Canadian dollars unless otherwise noted.

15 Oct 2009

NYU Langone Medical Center to establish a schizophrenia research center with $10M NIMH grant

NYU Langone Medical Center has received a five-year, $10 million grant from the National Institute of Mental Health (NIMH) to establish a Silvio O. Conte Center for the Neuroscience of Mental Disorders. The center, named after the late Silvio O. Conte, a U.S. congressman and advocate for mental health research, will study the onset of schizophrenia. Schizophrenia is a disease with cognitive dysfunction, affecting approximately one percent of the population worldwide.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

HERO House granted 501 (c) (3) status by the Federal Government

HERO House, a consumer-driven advocacy and vocational center for persons suffering from severe mental illness, announced today, that it has become a free-standing not-for-profit agency and has been granted 501 (c) (3) status by the Federal Government designated as a public charity eligible to receive tax-deductible gifts and donations.

14 Oct 2009

New neurosurgical procedure may prove helpful for patients with treatment-resistant depression

A new neurosurgical procedure may prove helpful for patients with treatment-resistant depression. Bilateral epidural prefrontal cortical stimulation (EpCS) was found generally safe and provided significant improvement of depressive symptoms in a small group of patients, according to lead researcher Ziad Nahas, M.D. at the Medical University of South Carolina. The data are reported in the on-line issue of Biological Psychiatry.

14 Oct 2009

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Cochlear implant inventor chosen for neuroscience research

Dr. Michael Merzenich, PhD - renowned neuroscientist, university professor, cochlear implant inventor, brain plasticity expert and tech entrepreneur - was formally inducted in the Institute of Medicine (IOM) today in Washington, D.C.

13 Oct 2009

Mechanism by which gene associated with autism and schizophrenia influences behavior identified

A Stanford University School of Medicine researcher has pinpointed the mechanism by which a gene associated with both autism and schizophrenia influences behavior in mice. And just recently, he received a $1.65 million government grant to expand his efforts to include many more such genes.

13 Oct 2009

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Titan Pharmaceuticals, Inc today announced that Vanda Pharmaceuticals, Inc. reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanapt™ (iloperidone) in the U.S. and Canada. Fanapt™, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults.

13 Oct 2009

CED to host popular STREAK program

CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced that it will host the next installment of its popular STREAK program, to be held Thursday, Oct. 8 from 3 p.m. to 5 p.m.

12 Oct 2009

Study finds that stranger homicide by people with schizophrenia rare

International study led by Sydney researchers shows homicides of strangers by people with schizophrenia are exceptionally rare and unpredictable events

12 Oct 2009

Homicides of strangers by people with schizophrenia are exceptionally rare, says study

International study led by Sydney researchers shows homicides of strangers by people with schizophrenia are exceptionally rare and unpredictable events

12 Oct 2009

WCMC-Q program highlights the importance of mental health to overall physical health

Mental health professionals from Weill Cornell Medical College in Qatar and the community highlighted the importance of mental health to overall physical health during a presentation Sunday as part of the medical college's recognition of World Mental Health Day.

12 Oct 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

Targacept presents data from Phase 2b clinical trial of TC-5214

Researchers find the genetic mutation that is linked with changes in brain development

New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses

SAMHSA honors contributors to mental health recovery at the 2009 Voice Awards

Negative symptoms represent an attractive target for drug development

Medicure announces results of operations for the three months ended August 31, 2009

NYU Langone Medical Center to establish a schizophrenia research center with $10M NIMH grant

Abbott announces financial results for the third quarter ended Sept. 30, 2009

HERO House granted 501 (c) (3) status by the Federal Government

New neurosurgical procedure may prove helpful for patients with treatment-resistant depression

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Positive results from Alkermes' ALKS 33 clinical trials announced

Johnson & Johnson announces financial results for the third quarter of 2009

Cochlear implant inventor chosen for neuroscience research

Mechanism by which gene associated with autism and schizophrenia influences behavior identified

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

CED to host popular STREAK program

Study finds that stranger homicide by people with schizophrenia rare

Homicides of strangers by people with schizophrenia are exceptionally rare, says study

WCMC-Q program highlights the importance of mental health to overall physical health

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Schizophrenia News and Research

Latest Schizophrenia News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in